Epsilon Healthcare Ltd (ASX: EPN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Epsilon Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.78 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
389.10 million
Earnings per share
-0.003
Dividend per share
N/A
Year To Date Return
-39.39%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Epsilon Healthcare Ltd (ASX: EPN)
Latest News
Share Gainers
Why Kogan, LiveTiles, Speedcast, & THC Global shares climbed higher today
Share Gainers
Why these ASX cannabis shares are rocketing higher today
52-Week Lows
Why Flight Centre and these ASX shares just dropped to 52 week lows
Share Gainers
Why this ASX cannabis stock has climbed 2% higher this morning
Share Market News
Here's how these ASX cannabis shares have performed in 2019
⏸️ Investing
Can these ASX pot stocks deliver growth in 2019?
Share Fallers
Cann Group Ltd (ASX:CAN) and the rest of the cannabis industry are being smoked today
Share Market News
How did these local pot stocks react to Canada legalising cannabis?
Share Gainers
Why these cannabis shares smoked the market on Tuesday
⏸️ Investing
Are Aussie pot stocks set to smoke the market in October?
⏸️ Investing
Up in smoke: What happened to the ASX pot stocks?
Share Market News
Insiders have been buying these 3 ASX shares
EPN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Epsilon Healthcare Ltd
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
EPN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Apr 2026 | $0.02 | $0.00 | 0.00% | 36,000 | $0.02 | $0.02 | $0.02 |
| 23 Apr 2026 | $0.02 | $0.00 | 0.00% | 28,719 | $0.02 | $0.02 | $0.02 |
| 22 Apr 2026 | $0.02 | $0.00 | 0.00% | 7,800 | $0.02 | $0.02 | $0.02 |
| 21 Apr 2026 | $0.02 | $0.00 | 0.00% | 104,045 | $0.02 | $0.02 | $0.02 |
| 20 Apr 2026 | $0.02 | $0.00 | 0.00% | 14,010 | $0.02 | $0.02 | $0.02 |
| 17 Apr 2026 | $0.02 | $0.00 | 0.00% | 908,721 | $0.02 | $0.02 | $0.02 |
| 16 Apr 2026 | $0.02 | $0.00 | 0.00% | 765,720 | $0.02 | $0.02 | $0.02 |
| 15 Apr 2026 | $0.02 | $0.00 | 0.00% | 92,497 | $0.02 | $0.02 | $0.02 |
| 13 Apr 2026 | $0.02 | $0.00 | 0.00% | 1,115,063 | $0.02 | $0.02 | $0.02 |
| 10 Apr 2026 | $0.02 | $0.00 | 0.00% | 1,869 | $0.02 | $0.02 | $0.02 |
| 09 Apr 2026 | $0.02 | $0.00 | 0.00% | 80,000 | $0.02 | $0.02 | $0.02 |
| 08 Apr 2026 | $0.02 | $0.00 | 0.00% | 160,397 | $0.02 | $0.02 | $0.02 |
| 07 Apr 2026 | $0.02 | $0.00 | 0.00% | 96,488 | $0.02 | $0.02 | $0.02 |
| 02 Apr 2026 | $0.02 | $0.00 | 0.00% | 131,365 | $0.02 | $0.02 | $0.02 |
| 01 Apr 2026 | $0.02 | $0.00 | 0.00% | 295,000 | $0.02 | $0.02 | $0.02 |
| 31 Mar 2026 | $0.02 | $0.00 | 0.00% | 6,751 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Jan 2026 | Zoe Hutchings | Buy | 307,934 | $10,856 |
On-market trade. 10,856.78 (including brokerage)
|
| 30 Dec 2025 | Zoe Hutchings | Buy | 519,426 | $19,106 |
On-market trade. including brokerage
|
| 19 Dec 2025 | Zoe Hutchings | Buy | 40,000 | $1,004 |
On-market trade.
|
| 25 Jul 2025 | Alan Beasley | Issued | 10,000,000 | $240,000 |
Issue of options.
|
| 25 Jul 2025 | Peter Giannopoulos | Issued | 25,000,000 | $600,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Preston Beasley | Non-Executive DirectorNon-Executive Chairman | Aug 2016 |
Mr Beasley is a company director with over 30 years of experience, having served many small, medium and large company Boards including startups, IPOs and turnarounds. A former director of the Australian subsidiaries of Bankers Trust, Goldman Sachs and BNP Paribas, Alan has the corporate reach, expertise and experience to advise and assist the company in the corporate and capital markets environment.
|
| Mr Peter Giannopoulos | Chief Executive OfficerExecutive Director | May 2023 |
Mr Giannopoulos brings more than 25 years of experience across the Australian healthcare ecosystems. Previously Peter was CEO of Cell Therapies Pty Ltd, an Australian based globally active commercial contract development and manufacturing company with a specialization in cell and gene therapies and cellular immunotherapy products.
|
| Ms Zoe Hutchings | Non-Executive Director | Jun 2024 |
Ms Hutchings has a career leading pharmaceutical and healthcare business units to identify opportunities for diversification, growth and to realize long term profitability in multiple geographical jurisdictions. Her leadership of the company-wide strategy at Sandoz Pharmaceuticals, encompassing a start-up business unit and cross company strategy, led to a return to margin accretive growth. Concurrently, Zoe has skills acquired in the pharmaceutical and healthcare industry in multi-product franchises, at various product life cycle stages from launch to patent expiry, to generic portfolios.
|
| Mr Daniel Kaplon | Chief Financial OfficerCompany Secretary | Aug 2025 |
-
|
| Daniel Kaplon | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Watercrest Asset Management Pty Ltd | 35,828,878 | 9.21% |
| Alexander Hotel Investments Pty Ltd | 21,250,000 | 5.46% |
| Cyrene Holdings Pty Ltd <Cyrene A/C> | 16,771,121 | 4.31% |
| Mr Lloyd Stafford Taylor | 12,687,088 | 3.26% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 10,911,556 | 2.80% |
| HSBC Custody Nominees (Australia) Limited | 10,517,481 | 2.70% |
| Mr Alan Preston Beasley | 10,500,000 | 2.70% |
| Dash & Co Assets Pty Ltd <Dash And Co Super Fund A/C> | 10,000,000 | 2.57% |
| Fennell Church Pty Limited <Fennell Church Prop Unit A/C> | 8,438,499 | 2.17% |
| Health360 Investment Management Inc | 7,052,880 | 1.81% |
| Giannopoulos Superannuation Nominees Pty Ltd <Giannopoulos Super Fund A/C> | 7,000,000 | 1.80% |
| S Bentley & Co Pty Ltd <S Bentley & Co Family A/C> | 5,555,556 | 1.43% |
| Hollow Sword Blade Company Pty Ltd | 4,000,000 | 1.03% |
| Mr Gary John Radcliff & Mrs Debbi Lee Radcliff | 3,955,700 | 1.02% |
| Barcoo Holdings Pty Ltd <Wyan Family Investments> | 3,795,824 | 0.98% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,540,844 | 0.91% |
| Mr George Daaboul | 3,000,000 | 0.77% |
| Meta Growth Corp | 2,942,489 | 0.76% |
| Ms Cherese Richelle Taylor & Mr Lauie Gabriel Dok | 2,940,000 | 0.76% |
| Celtic Capital Pty Ltd | 2,888,872 | 0.73% |